skip to main content
Jason Markwell

Jason Markwell

Direct: 416.863.3383
Fax: 416.863.9171

Jason Markwell is an accomplished intellectual property litigator.

Jason represents multinational and domestic corporations in patent infringement and validity actions, judicial review applications, and in contentious regulatory matters.  He has particular expertise in cases involving the pharmaceutical and biotechnology industries, as well as matters relating to technology, financial services, and energy.  He also has experience in trademark, copyright and trade secret litigation.

Jason has been recognized as a leading advocate by Chambers and Partners, Lexpert, IAM Patent 1000, Best Lawyers Canada, Who’s Who Legal, and Benchmark Legal. Jason is active in various intellectual property organizations, including the Intellectual Property Institute of Canada and AIPPI.  He is a member of the Advocates’ Society and a Fellow of the Litigation Counsel of America.

Jason has appeared before the Supreme Court of Canada, the Federal Court of Appeal, the Federal Court, the Ontario Superior Court, and a number of administrative tribunals. Prior to joining Belmore Neidrauer in 2016, Jason was the Canadian leader of life sciences and healthcare at a global law firm.


  • Called to the Ontario Bar, 1999
  • Osgoode Hall Law School, LL.B., 1997
  • Queen's University, B.Sc.H., 1994


  • IAM Patent 1000: The World’s Leading Patent Professionals 2018: Litigation
  • Who’s Who Legal: Patents 2018
  • Managing Intellectual Property IP Star 2018
  • Lexpert/Thomson Reuters' Canadian Legal Lexpert Directory, 2018 – Consistently Recommended in Litigation - Intellectual Property and Intellectual Property and Most Frequently Recommended in Biotechnology
  • Best Lawyers in Canada, 2018: Biotechnology Law; Intellectual Property Law
  • Lexpert/Thomson Reuters' Canadian Legal Lexpert Directory, 2017 – Consistently Recommended in Litigation - Intellectual Property and Biotechnology and Repeatedly Recommended in Intellectual Property
  • Benchmark Litigation: Provincial Litigation Star (2017) – Ontario: Intellectual Property
  • Who’s Who Legal Life Sciences 2017: Patent Litigation
  • Benchmark Canada - Intellectual Property Litigator of the Year
  • 2017 WIPR Leaders Directory
  • 2016 Lexpert US/Canada Cross-Border Guide - Litigation
  • Chambers Canada 2017:  Intellectual Property Litigation, Band 3 
  • 2016 IP Star, Managing Intellectual Property 
  • Best Lawyers in Canada, 2017 – Intellectual Property Law; Biotechnology Law 
  • Benchmark Canada - recognized as a Local Litigation Star (2016) - Ontario: Intellectual Property 
  • LEXPERT® Magazine - Consistently Recommended for Biotechnology and Repeatedly Recommended in the categories of Intellectual Property and Litigation - Intellectual Property
  • IAM Patent 1000: The World's Leading Patent Professionals 2016: Litigation  
  • 2015 IP Star, Managing Intellectual Property
  • Best Lawyers in Canada, 2015-2016 – Intellectual Property Law; Biotechnology Law 
  • Who’s Who Legal Canada, 2014-2015 – Patents
  • Canadian Legal Lexpert Directory, 2015: recommended in Intellectual Property
  • Canadian Legal Lexpert Directory, 2014 – recommended in Biotechnology; Intellectual property
  • Chambers Global: The World’s Leading Lawyers for Business, 2011-2016 – Intellectual Property: Litigation
  • Benchmark Canada, 2012-2014 – recognized as a future litigation star in Ontario and Local Litigation Star (2015)
  • Best Lawyers in Canada, 2014 – Intellectual Property Law
  • Canadian Legal Lexpert Directory, 2013 – recommended in Biotechnology; Intellectual property; Litigation – Intellectual Property
  • Martindale-Hubbell – ranked BV (Distinguished) in Intellectual Property, Patents and Administrative Law
  • IAM Patent 1000 – World’s Leading Patent Practitioners, 2012
  • IAM 250 – World’s Leading Patent Litigators


Date Title Type
Jun 22, 2016 Revised Biotech Patent Guidelines in Canada Article


Date Case Title Expertise
Jul 13, 2018 2018 FC 736 Eli Lilly Canada Inc. et al v. Apotex Inc.
We represented Eli Lilly, Daiichi and Ube in this application relating to a patent covering Eli Lilly’s EFFIENT product.


Apr 10, 2018 Federal Court File Nos. T-598-17 through T-605-17 AbbVie Corporation et al v Samsung Bioepis Co. Ltd.
We represented AbbVie in a series of eight applications under the Patented Medicines (Notice of Compliance) Regulations relating to AbbVie’s ...


Apr 09, 2018 Federal Court File No. T-1355-17 Samsung Bioepis Co., Ltd. v AbbVie Biotechnology Ltd. et al.
We represented AbbVie in a patent impeachment action brought by Samsung Bioepis in relation to Samsung Bioepis’ biosimilar to AbbVIe’s ...


Feb 06, 2018 2018 FCA 32 Apotex Inc. v. Bayer Inc.
We successfully represented Bayer Inc. on this important appeal, which upheld the patentee’s right to elect its damages.


Jul 24, 2017 2017 FCA 161 Idenix Pharmaceuticals, Inc. v. Gilead Pharmasset al.
We successfully represented Gilead in a patent case relating to antiviral compounds for use in the treatment of Hepatitis C. Gilead proved that Ide...


More Cases


  • Law Society of Upper Canada
  • The Advocates’ Society
  • Intellectual Property Institute of Canada
  • International Association for the Protection of Intellectual Property (AIPPI)
  • Chair, AIPPI Canada — Litigation Committee
  • Litigation Counsel of America, Fellow
Jason Markwell

Jason Markwell 


Direct: 416.863.3383
Fax: 416.863.9171

© 2015 Belmore Neidrauer LLP | Legal Disclaimer | Privacy Policy